Healthcare / Medical DevicesNasdaqCM
$10.60
-0.07 (-0.68%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-16.9M · quality 68.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
19/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$7M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-71.8%
↓Gross Margin
N/A
•Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2017–2025 · 8 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.80x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-19.5M · FCF $-15.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | — | — | — | — | — | — | — | $31243.00 | $186552.00 | $422111.00 |
| Net Income | $-19.5M | $-19.5M | $-21.8M | $-23.5M | $-24.7M | $-16.5M | $-9.1M | $-7.6M | $-13.0M | $-7.8M |
| EBITDA | $-20.4M | $-20.4M | $-23.3M | $-24.7M | $-24.4M | $-16.7M | $-9.0M | $-7.6M | $-7.7M | $-6.0M |
| EPS | -33.06 | -33.06 | -44.53 | -66.85 | -77.00 | -66.50 | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — | 100.0% | 0.6% |
| Operating Margin | — | — | — | — | — | — | — | -24566.5% | -4210.5% | -1445.9% |
| Net Margin | — | — | — | — | — | — | — | -24406.7% | -6991.5% | -1845.8% |
| Balance Sheet | ||||||||||
| Debt/Equity | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 | — | — | — | — | — |
| Current Ratio | 11.89 | 11.89 | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||
| Free Cash Flow | $-15.6M | $-15.6M | $-16.9M | $-18.9M | $-15.7M | $-12.2M | $-7.9M | $-6.3M | $-6.4M | $-4.2M |
| Returns | ||||||||||
| ROE | -71.8% | -71.8% | -51.8% | -50.9% | -63.7% | -30.4% | -128.7% | -770.3% | -640.5% | 70.0% |
| Valuation | ||||||||||
| P/B | 0.23 | 0.23 | 1.37 | 1.29 | 1.49 | — | — | — | — | — |
| Growth & Yield | ||||||||||
| Revenue Growth | — | — | — | — | — | — | — | -83.3% | -55.8% | — |
| EPS Growth | 25.8% | 25.8% | 33.4% | 13.2% | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-91.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-44.53 → -33.06
Residual
-91.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.